scholarly journals Alzheimer's disease progression model based on integrated biomarkers and clinical measures

2014 ◽  
Vol 35 (9) ◽  
pp. 1111-1120 ◽  
Author(s):  
Yue Qiu ◽  
◽  
Liang Li ◽  
Tian-yan Zhou ◽  
Wei Lu
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Model Based ◽  
Progression Model ◽  
Disease Progression Model ◽  
Clinical Measures

scholarly journals Influence of publication year, add-on design, and geographical region on the progression of Alzheimer’s disease: a modeling analysis of literature aggregate data

2020 ◽  
Author(s):  
ningyuan zhang ◽  
Xijun Zheng ◽  
Hongxia Liu ◽  
Qingshan Zheng ◽  
Lujin Li
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Disease Assessment ◽  
Progression Rate ◽  
Progression Model ◽  
Geographical Regions ◽  
Significant Difference ◽  
Disease Progression Rate ◽  
Disease Progression Model

Abstract Background Our objective was to develop a disease progression model for cognitive decline in Alzheimer’s disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on trial design, and geographical regions. Methods Placebo-controlled randomized AD clinical trials were systemically searched in public databases. Longitudinal placebo response (mean change from baseline in the cognitive subscale of the Alzheimer’s Disease Assessment Scale [ADAS-cog]) and the corresponding demographic information were extracted to establish a disease progression model. Covariate screening and subgroup analyses were performed to identify potential factors affecting the disease progression rate. Results A total of 142 publications (148 trials) were included in this model-based meta-analysis. The typical disease progression rate was 5.82 points per year. The baseline ADAS-cog score was included in the final model using an inverse-U type function. Age was found to be negatively correlated with disease progression rate. After correcting the baseline ADAS-cog score and the age effect, no significant difference in disease progression rate was found between trials published before and after 2008, and between trials using add-on design and those that did not use add-on design. However, a significant difference was found among different trial regions. Trials in East Asian countries showed the slowest decline rate and the largest placebo effect. Conclusions Our model successfully quantified AD disease progression by integrating baseline ADAS-cog score and age as important predictors. These factors and geographic location should be considered when optimizing future trial designs and conducting indirect comparisons of clinical outcomes.

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

2010 ◽  
Vol 7 (2) ◽  
pp. 151-160 ◽  
Author(s):  
Kaori Ito ◽  
Brian Corrigan ◽  
Qinying Zhao ◽  
Jonathan French ◽  
Raymond Miller ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Cognitive Deterioration ◽  
Progression Model ◽  
Disease Progression Model

scholarly journals Disease progression modeling of Alzheimer’s disease according to education level

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ko Woon Kim ◽  
Sook Young Woo ◽  
Seonwoo Kim ◽  
Hyemin Jang ◽  
Yeshin Kim ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Disease Modeling ◽  
Education Level ◽  
Mixed Effect ◽  
Progression Model ◽  
Education Group ◽  
Disease Progression Model ◽  
End Stage

Abstract To develop a disease progression model of Alzheimer’s disease (AD) that shows cognitive decline from subjective cognitive impairments (SCI) to the end stage of AD dementia (ADD) and to investigate the effect of education level on the whole disease spectrum, we enrolled 565 patients who were followed up more than three times and had a clinical dementia rating sum of boxes (CDR-SB). Three cohorts, SCI (n = 85), amnestic mild cognitive impairment (AMCI, n = 240), and ADD (n = 240), were overlapped in two consecutive cohorts (SCI and AMCI, AMCI and ADD) to construct a model of disease course, and a model with multiple single-cohorts was estimated using a mixed-effect model. To examine the effect of education level on disease progression, the disease progression model was developed with data from lower (≤ 12) and higher (> 12) education groups. Disease progression takes 274.3 months (22.9 years) to advance from 0 to 18 points using the CDR-SB. Based on our predictive equation, it takes 116.5 months to progress from SCI to AMCI and 56.2 months to progress from AMCI to ADD. The rate of CDR-SB progression was different according to education level. The lower-education group showed faster CDR-SB progression from SCI to AMCI compared to the higher-education group, and this trend disappeared from AMCI to ADD. In the present study, we developed a disease progression model of AD spectrum from SCI to the end stage of ADD. Our disease modeling provides us with more understanding of the effect of education on cognitive trajectories.

scholarly journals Disease progression modeling of Alzheimer’s disease according to education level

2019 ◽  
Author(s):  
Ko Woon Kim ◽  
Sook Young Woo ◽  
Seonwoo Kim ◽  
Yeshin Kim ◽  
Hyemin Jang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Disease Progression ◽  
Education Level ◽  
Disease Stage ◽  
Mixed Effect ◽  
Progression Model ◽  
Education Group ◽  
Disease Progression Model

Abstract Background To develop a disease progression model of Alzheimer’s disease (AD) that shows cognitive decline from subjective cognitive impairments (SCI) to dementia and to investigate the effect of education level on the whole disease spectrum. Methods We enrolled 565 patients who were followed up more than three times and had a clinical dementia rating sum of boxes (CDR-SB) score. Three cohorts, SCI (n=85), amnestic mild cognitive impairment (AMCI, n=240), and AD dementia (ADD, n=240), were overlapped in two consecutive cohorts (SCI and AMCI, AMCI and ADD) to construct a model of disease course, and a model with multiple single-cohorts was estimated using a mixed-effect model. To examine the effect of education level on disease progression, the disease progression model was developed with data from lower (≤12) and higher (>12) education groups. Results Disease progression takes 277.0 months (23.1 years) to advance from 0 to 18 points using the CDR-SB score. Based on our predictive equation, it takes 101.9 months to progress from SCI to AMCI and 71.1 months to progress from AMCI to ADD. The rate of CDR-SB progression was different according to education level. The lower-education group showed faster CDR-SB progression from SCI to AMCI compared to the higher-education group, and this trend disappeared from AMCI to ADD. Conclusion In the present study, we developed a disease progression model of AD spectrum from preclinical to the end stage of the disease. Our findings suggest that the contribution of education to cognitive decline varies depending on disease stage.

scholarly journals A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease

2018 ◽  
Vol 37 (21) ◽  
pp. 3047-3055 ◽  
Author(s):  
Guoqiao Wang ◽  
Scott Berry ◽  
Chengjie Xiong ◽  
Jason Hassenstab ◽  
Melanie Quintana ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Disease Progression ◽  
Autosomal Dominant ◽  
Progression Model ◽  
Autosomal Dominant Alzheimer’S Disease ◽  
Disease Progression Model

scholarly journals Testing whether the progression of Alzheimer's disease change with the year of publication, additional design and geographical area: a modeling analysis of literature aggregate data

2020 ◽  
Author(s):  
ningyuan zhang ◽  
Xijun Zheng ◽  
Hongxia Liu ◽  
Qingshan Zheng ◽  
Lujin Li
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Disease Assessment ◽  
Progression Rate ◽  
Progression Model ◽  
Geographical Regions ◽  
Significant Difference ◽  
Disease Progression Rate ◽  
Disease Progression Model

Abstract Background Our objective was to develop a disease progression model for cognitive decline in Alzheimer’s disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on trial design, and geographical regions. Methods Placebo-controlled randomized AD clinical trials were systemically searched in public databases. Longitudinal placebo response (mean change from baseline in the cognitive subscale of the Alzheimer’s Disease Assessment Scale [ADAS-cog]) and the corresponding demographic information were extracted to establish a disease progression model. Covariate screening and subgroup analyses were performed to identify potential factors affecting the disease progression rate. Results A total of 134 publications (140 trials) were included in this model-based meta-analysis. The typical disease progression rate was 5.82 points per year. The baseline ADAS-cog score was included in the final model using an inverse-U type function. Age was found to be negatively correlated with disease progression rate. After correcting the baseline ADAS-cog score and the age effect, no significant difference in disease progression rate was found between trials published before and after 2008, and between trials using add-on design and those that did not use add-on design. However, a significant difference was found among different trial regions. Trials in East Asian countries showed the slowest decline rate and the largest placebo effect. Conclusions Our model successfully quantified AD disease progression by integrating baseline ADAS-cog score and age as important predictors. These factors and geographic location should be considered when optimizing future trial designs and conducting indirect comparisons of clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document